First Test That Predicts Severe Outcomes In COVID-19 Patients Receives CE Mark
Executive Summary
MeMed’s test measures immune system response to assess a patient’s COVID-19 trajectory.
You may also be interested in...
MeMed Secures $93M Financing To Commercialize Diagnostics Platform
The company will use the money to fund its US commercialization strategy and continue to develop its host response-based product pipeline.
Exec Chat: MeMed Improves Diagnostics To Combat Antimicrobial resistance
Kfir Oved, co-founder and CTO of MeMed, talked to Medtech Insight about diagnostic testing that can differentiate bacterial and viral infections to fight antimicrobial resistance.
Sensyne Algorithm For COVID-19 Risk Prediction Gets UK Regulatory Approval
Sensyne obtained UK regulatory approval for its SYNE-COV machine learning algorithm to assess the long-term risks of COVID-19.